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There is concern thatpreviouslyaccumulated bone lead stores mayconstitute an internal source
ofexposure, particularly during periods ofincreased bone mineral loss (e.g., pregancy, lacta-
tion, and menopause). Furthermore, the contribution oflead mobilized from bone to plasma
maynot beadequatelyreflectedbywhole-blood leadlevels.Thispossibilityisespeciallyal ing
because plasma is the main circulatory compartment oflead that is available to cross cell mem-
branes anddeposit insoft tissues. Westudied 26residentsofMexicoCitywhohadnohistoryof
occupational lead exposure. Two samples ofvenous blood were collected from each individual.
One samplewas analyzed byinductivelycoupledplasma-magetic sector mass spectrometryfor
whole-blood lead levels. The other sample was centriuged to separate plasma, which was then
isolated and analyzed for lead content bythe sme anaytical technique. Bone leadlevels in the
tibia and patella were determined with a spot-source 109Cd K-X-ray fluorescence intment
Mean lead concentratons were 0.54 pgll in plasma, 119 pgIl in whole blood, and 23.27 and
11.71 pg/g bone mineral in the patella and tibia, respectively. The plasma-to-whole-blood lead
concentration ratiosrangedfrom0.27% to 0.70%. Whole-blood leadlevl was higblycorrelated
with plasma lead level and accounted for 95% ofthe variability ofplasma lead concentations.
Patella and tibia lead levels were also highly correlated with plasma lead levels. The bivariate
regression coefficients ofpatella and tibia on plasma lead were 0.034 (p.0.001) and 0.053
(p0.001), respectively. In a multivarate regression model ofplasma lead levels that induded
whole-blood lead, patellaleadlevelremaiined an independent predictor ofplasma lead level (p-
0.007, p<O.001). Our data suggest that although whole-blood lead levels are highly correlated
with plasma lead levels, lead levels in bone (particularly trabecular bone) exert an additional
independent influence on plasma lead levels. It will be important to determine whether the
degree ofthis influence increases during times ofheightened bone turnover (e.g., pregnancyand
lactation). Key word blood, bone, K-X-ray fluorescence, lead, plam Enron HealhPpect
106:473-477 (1998). [Online6July 1998]
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Population blood lead levels have been
decreasing in response to environmental
measures that restrict emissions oflead (1).
However, some evidence suggests that elevat-
ed exposure to lead may continue for many
years, even after exposure to environmental
sources has been reduced. This may occur
primarily due to the mobilization ofendoge-
nous bone lead stores (4. The skeleton is the
primary site ofstorage for about 95% oflead
in the adult human body (3). Toxicokinetic
studies have demonstrated that although the
half-life of lead in bone is on the order of
years to decades, bone is a dynamic organ
with respect to lead, engaging in a constant
low-level interchange with soft-tissue ele-
ments (4-7). Recent data from Cake et al.
(8), Gulson et al. (5,% and Smith et al. (10)
indicate that the skeleton is an important
source ofendogenous lead exposure in indi-
viduals with a history ofhigh-level occupa-
tional or environmental lead exposure.
The contribution ofendogenous sources
of lead to plasma may be important, but a
substantial change in plasma lead may go
unnoticed when lead is measured in whole
blood (the usual method of evaluation)
because less than 2% oftotal blood lead is
free in plasma. Moreover, factors control-
ling the relative partitioning ofcirculatory
lead into the plasma are not well known,
although it has been suggested that plasma
lead levels maybetter reflect the labile, bio-
logically active fraction of circulatory lead
most available for distribution to and from
peripheral tissues.
Until recently, epidemiological studies
on the toxicological significance ofhuman
bone lead stores have required the use of
invasive methods. However, in vivo K-X-
ray fluorescence (K-XRF) now permits
noninvasive studies in which bone lead
level serves as a measure of bone lead
reserves (11). In this study, we examined
the relation among lead levels in bone,
plasma, and blood of a sample of healthy
volunteers who had no occupational histo-
ry oflead exposure.
Methods
StudyPopulation
We recruited 26 healthy individuals who
had not been occupationally exposed to
lead; the group included 20 women (mean
age 36 years, range 24-54 years) and 6 men
(mean age 38, range 19-70 years). Only 5
participants were over 50 years ofage. The
main risk factors for lead exposure in the
group were residence in Mexico City for
more than 10 years (88%) and use oflead-
glazed ceramics for cooking and storing
food (58%) (14. All participants had pro-
vided a blood sample and had undergone at
least one bone lead measurement in the 1-3
months before this study. The individuals
selected for this study constituted a sample
designed to reflect the patella (trabecular)
bone lead concentrations observed in previ-
ous studies of the general population of
Mexico City (13). We selected individuals
to represent three strata with the following
cutoff points: >10 pg of lead/g of bone
mineral (n = 7); 10.1-20.0 pg/g (n = 7);
and >20 pg/g (n = 11). On 22 May 1996,
all study subjects had two blood samples
taken: one for whole-blood lead measure-
ment and the other for plasma lead mea-
surement. After preparation and labeling,
plasma and blood specimens were shipped
to the University ofCalifornia, Santa Cruz,
for lead determination.
Plasmaand Blood Lead
Measurements
Study subjects attended our research clinic
and were instructed beforehand to fast
overnight, as meals consumed before the
collection ofserum samples may transiently
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alter steady-state serum lead levels (14). As
demonstrated by Smith et al. (15), the
accurate and precise determination ofplas-
ma and serum lead levels depends on
meticulous processing techniques, includ-
ing control oflead contamination, hemoly-
sis, and redistribution of lead due to anti-
coagulants, and, in the case ofserum sam-
ple collection, the time interval for whole-
blood dotting before separation of serum.
Before the collection ofvenous blood (15
ml total) through a butterfly catheter (19-
gauge), each subject's arm was washed with
ultrapure water and disinfected with
reagent-grade alcohol. An initial whole-
blood sample of 3 ml was collected in a
low-lead container (Vacutainer, B-D
#367734; Becton-Dickinson, Franklin
Lakes, NJ) for total lead analysis; immedi-
ately thereafter, the catheter tubing was
severed at a point distal to the venipunc-
ture, and a second whole-blood sample of
13 ml for plasma separation was collected
via gravity-fed phlebotomy (no vacuum)
into a polyethylene tube containing 75
USP of low-lead sodium heparin [Sigma
#H-3393, 0.1 pg Pb/USP unit (15)]. The
13-ml whole-blood sample was immediate-
ly enclosed in plastic wrap and centrifuged
at 2000 rpm (800g) for 10 min at room
temperature. The separated plasma fraction
(5-6 ml) was then pipetted into a polyeth-
ylene bottle with a polyethylene pipette
and immediately frozen.
We conducted all blood collections,
plasma and whole-blood processing, and
sample analyses under trace metal-free
HEPA air-filtered laboratory (Class 100)
conditions using ultraclean trace-metal
techniques (16) developed at the University
ofCalifornia, Santa Cruz. Materials used in
sample collection and in the laboratory
(Teflon, polyethylene, and polypropylene)
were acid-cleaned by established proce-
dures (15,16). Reagents, including water
and acids, were high-purity grade. For
analyses, the entire 5-6 ml plasma sample
or 0.5-ml aliquot ofwhole blood was trans-
ferred into a Teflon digestion vial, evapo-
rated and digested for 8 hr in 5 ml ofhot
16 N HNO3, evaporated to dryness, and
redissolved in 1 N HNO3. Sample lead
and iron levels were measured indepen-
dently with a Finnegan Element inductive-
ly coupled plasma (ICP) high-resolution
mass spectrometer in multi-isotope count-
ing mode, with both internal and external
standardization (15,14. We used National
Institute of Standards and Technology
(NIST) standard reference materials (SRM)
955 (blood) and 1577 (bovine liver) to
evaluate analytical accuracy. This method
yields a measurement precision of <0.5%
RSD (relative standard deviation) for lead
concentrations of >0.05 ppb (15,1X. The
analytical detection limit was 0.01 ppb.
Lead contamination ofthe plasma sam-
ples, either from external sources or from
erythrocytic lead due to hemolysis, is a sig-
nificant potential modifier of true plasma
lead levels. We evaluated lead contamina-
tion from external sources by determining
the total lead and stable lead isotopic com-
positions ofprocedural collection and pro-
cessing blanks and comparing the values
obtained with levels measured in whole
blood and plasma. Separately, the low-lead
heparin anticoagulant was shown to con-
tribute a negligible amount of lead (8 pg
Pb) to the 13-ml whole-blood sample used
forplasma lead separation (15).
Although potential contamination of
plasma samples was evaluated here, quanti-
tative correction ofsample lead concentra-
tions for external lead contamination asso-
ciated with sample collection and process-
ing was not attempted because there is no
reliable and accurate method to determine
the relative contribution ofblank contami-
nant lead to a collected plasma sample
(15). Although some fraction oftotal blank
lead undoubtedly partitions with the sepa-
rated plasma fraction, the amount is not
known and mayvarywith the physiochem-
ical nature ofthe lead and other biological
andphysical factors.
In contrast, measurable lead contami-
nation of plasma samples may arise from
lead redistributed from erythrocytes, partic-
ularly in cases of apparent hemolysis. To
evaluate the potential contribution of
hemolysis to plasma lead levels, whole-
blood iron and plasma iron levels were
measured. The rationale for measuring
plasma iron to evaluate hemolysis is based
on 1) the distribution of iron between the
erythrocyte cell fraction and the plasma, 2)
the relatively narrow and well-characterized
range of plasma iron levels considered
physiologically normal (0.5-1.75 pg/ml),
3) the sensitivity ofthe ICP-MS methodol-
ogy for determining relatively small
changes in sample iron levels, and 4) the
premise that increases in plasma iron levels
beyond physiologically normal levels would
reflect a nonphysiologic input ofboth iron
and lead from erythrocytes. A previous
study has substantiated this approach as a
sensitive indicator ofplasma contamination
from erythrocytes (15).
K-XRF Bone Lead Measurements
Bone lead was measured in each subject's
mid-tibia shaft (cortical bone) and patella
(trabecular bone) with a spot-source 109Cd
K-XRF instrument constructed at Harvard
University and installed in a research facili-
ty at the American British Cowdray
Hospital in Mexico City. The physical
principles, technical specifications, and val-
idation of this instrument have been
detailed elsewhere (18). The instrument
uses a 109Cd 7-ray source to provoke the
emission of fluorescent lead photons from
target tissue. The emitted photons are then
detected, arrayed in a spectrum, and count-
ed. The net lead signal is determined after
subtraction of Compton background
counts by a linear least-squares algorithm.
The lead fluorescence signal is then nor-
malized to the elastic or coherently scat-
tered y-ray signal, which arises predomi-
nantly from the calcium and phosphorus
present in bone mineral. The unit of mea-
sure so derived is micrograms of lead per
gram ofbone mineral.
Calibration is performed using lead-
dopedphantoms ofwhich the truelead con-
centration has been verifiedbydirectchemi-
cal measurements using ICP-MS (18).
Because the instrument provides a continu-
ous unbiased point estimate that oscillates
around the true bone lead value, negative
point estimates are sometimes produced
when the true bone lead value is close to
zero. Validation studies ofthe instrument
we used have indicated a fairly high degree
ofprecision and accuracy ofpoint and mea-
surement uncertaintyestimates, with chemi-
cal analyses in studies oflead-doped phan-
toms usedforcomparisons (18).
For the presentstudy, 60-min measure-
ments were taken at the mid-shaft of the
left tibia and at the left patella after each
region had been washed with a 50% solu-
tion of isopropyl alcohol. The K-XRF
beam collimator was placed perpendicular
to the bone surface for the tibia and at 300
in the lateral direction forthepatella.
The reproducibility of bone measure-
ments using this particular K-XRF instru-
ment ishigh. Repeated measurements in 35
subjects showed ahigh intraclass correlation
of 0.84 and 0.82 for tibia and patella,
respectively.
StatisticalAnalysis
Plasma and blood lead levels were log trans-
formed to normalize theirdistributions. Bone
lead measurements were normallydistributed
and were modeled in their original scale. We
used the transformed plasma and blood vari-
ables in all statistical models. We first exam-
ined the bivariate relationships between plas-
ma lead and each biological marker oflead
(blood, patella, and tibia). We then con-
structed multivariate regression models in
which blood and bone lead variables were
included as predictors ofplasma lead. We
used these models to test thehypothesis that,
inaddition to bloodleadlevels, boneleadlev-
els are independent predictors ofplasma lead
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levels. Similar models were also run for plas-
ma-to-blood ratio as an outcome. All models
were adjusted for age, gender, and iron plas-
ma levels. We performed all regression analy-
ses with Stata Software (Stata Statistical
Software, release 4.0, Stata Corporation,
CollegeStation, Texas).
Results
Blank lead values for all ultraclean plasma
lead samples were uniformly low (<5% of
the total plasma lead sample) and thus were
considered negligible here. However, a sin-
gle subject was excluded from the data
analysis because ofexogenous lead contam-
ination of plasma, which was apparent
from the anomalous nonphysiologic stable
lead isotopic composition of the sample
compared with that ofwhole blood (data
not shown). No other cases of measurable
lead contamination ofplasma, either from
external or internal sources (the latter using
plasma iron levels as a marker) was evident
in samples from any of the 25 remaining
subjects. Two additional subjects did not
complete the 1-hr measurement for tibia
and were not included in the analysis relat-
ing tibia lead.
Descriptive statistics for biomarkers of
lead exposure are presented in Table 1. We
observed a high degree of correlation
between plasma and whole-blood lead lev-
els (Fig. 1, Table 2). Whole-blood lead lev-
els accounted for 95% of the variability
observed in plasma lead concentrations. In
the bivariate regression models, both patel-
la and tibia lead levels were also significant
predictors of plasma lead levels (Fig. 1,
Table 2). Patella lead accounted for 52% of
the variability. Plasma lead increased signif-
icantly as a function ofpatella lead concen-
tration. We observed an increase in the log
scale of plasma lead of 0.034 for each
microgram oflead per gram oflead in the
patella.
Tibia lead was also significantly and
positively associated with plasma lead; the
estimated regression coefficient between
the log plasma lead concentration and the
tibia lead level was 0.053. When we simul-
taneously included whole-blood lead and
each ofthe two bone lead variables, whole-
blood lead was a highly significant predic-
tor of plasma lead in both models (p <
0.001), as was patella lead (p = 0.005); tibia
lead was of borderline significance (p =
0.051) (Table 3). Log whole-blood lead
levels increased log plasma lead levels by
1.02 per unit ofwhole-blood lead, whereas
patella lead increased log plasma lead levels
by0.007 per unit ofbone lead.
Neither age, gender, nor plasma iron
levels remained as significant predictors of
plasma lead in multivariate models. The
Table 1. Descriptive summary statistics forplasma,whole-blood, and bone lead levels
Measurement Mean Median SD Minimum Maximum
Plasma lead (pg/I) 0.54 0.27 0.68 0.085 2.65
Plasma-to-blood lead ratio (%) 0.39 0.37 0.10 0.27 0.70
Blood (pg/I) 118.83 73.40 108.89 22.9 416.4
Tibia bone(pg/g) 11.71 10.31 10.61 -5.0 35.65
Patella bone (pg/g) 23.27 19.38 21.69 -3.21 92.82
Plasma iron(pg/g) 1.22 1.25 0.390 0.36 1.87
SD, standard deviation.
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inclusion of these variables in the models
did not change the observed associations
between plasma lead and other biomarkers
oflead exposure.
In our sample, the plasma-to-blood lead
concentration ratio also varied significantly
in relation to blood lead, patella lead, and
tibia lead concentrations (see Fig. 2). In a
regression model of the plasma-to-blood
lead concentration ratio that induded both
patella lead and whole-blood lead, patella
remained as a significant predictor (p<0.05),
whereas whole-blood lead was ofborderline
significance (p = 0.09). In contrast, in a
regression model of the plasma-to-blood
lead concentration ratio that included tibia
lead and whole-blood lead, whole-blood
lead remained as a significant predictor
(p<0.01), whereas tibia lead was of border-
linesignificance (p = 0.15).
Discussion
We found a strong relationship between
whole-blood lead and plasma lead levels in
these environmentally exposed adults. In
addition, we found a strong relationship
between bone lead and plasma lead concen-
trations, and patella (trabecular) bone lead
retained an independent influence on plas-
ma lead as well as on the plasma-whole-
blood lead ratio after adjusting for whole-
blood lead levels. This independence ofthe
-3
0 20 40u 0 80 100
Patellabone lead(gg/g bone)
Figure 1. The relationships of plasma to other
lead biomarkers, with superimposed smoothed
plots (Lowess smoother, bandwidth = 0.8). (A)
Blood lead.(B) Patella bone lead.(C)Tibia bone
lead. Plasma and blood lead were log trans-
formed.
Table 2. Bivariate regression models correlating
plasma lead levelswithwhole-blood and bone lead
levels
Constant Coefficient SE R2
Blood lead(pg/l) -6.16 1.37 0.05 0.95
Patellalead(pg/g) -1.91 0.034 0.006 0.52
Tibia lead(pg/g) -1.67 0.053 0.015 0.30
SE,standard error.
bone lead-plasma lead association from
whole-blood lead levels is consistent with
the potential role of the skeleton as an
important endogenous source oflabile lead
that may not be adequately discerned by
examining whole-blood lead levels. It also
indicates that skeletal sources oflead accu-
mulated from past exposures should be con-
sidered along with sources ofcurrent expo-
sure when exposure pathways are being
evaluated.
Tibia and patella lead levels were both
positively and significantly related to plasma
lead levels; however, the observed associa-
tion was stronger for patellalead. The blood
lead-adjusted standardized regression coeffi-
cients relating plasma lead level to patella
and tibia lead levels were 0.15 and 0.10,
respectively. A 10 lig/g increase in patella
lead level was associated with an increase of
7% in plasma lead level; the same change in
tibia lead level was associated with a 3.7%
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increase in plasmaleadlevels. The difference
between the results obtained for the two
bone lead markers could be attributed to the
fact that the patella consists predominantly
of trabecular bone, in which lead may be
more available for mobilization (19). This is
consistent with the greater blood perfusion
and turnover rates in trabecular than in cor-
tical bone (5) and with the results ofseveral
studies using tracer and standard metabolic
methods (6,13-15,20). In addition, it sup-
ports trabecular bone as the predominant
skeletal source of lead to the circulation
under steady-state conditions. However, the
fact that tibia lead was significantly associat-
ed with plasma lead levels and marginally
associated with blood lead-adjusted plasma
levels suggests that lead in cortical bone is
also released into the bloodstream. Cortical
bone composes approximately 80% ofskele-
tal mass and thus may exert strong influence
on plasma lead levels, even if its rate of
turnover is lower than that of trabecular
bone. The possible importance of cortical
bone in whole-body lead toxicodynamics
has also been suggested byreports indicating
that lead concentrations in cortical bone, as
opposed to concentrations in blood, were
linked to hypertension (21) and to a
decrease in birthweight (22).
Few investigators have described the
relationship between lead levels in bone and
whole blood and those in plasma. Most of
the published investigations have been con-
ducted among occupationally exposed indi-
viduals with levels ofexposure that are three
to four times higher than the levels encoun-
tered in the general urban population with
a history ofexposure to leaded gasoline and
other environmental sources (23). Bergdahl
and Skerfving (24) noted that among 19
retired lead smelter workers, the
100
Figure2. The reiationships of plasma-to-whole-
blood lead concentration ratio to other lead
biomarkers, with superimposed linear regres-
sion line. (A) Regression model for plasma-to-
whole-blood lead concentration ratioto whole-
blood lead concentration (y= 0.32 + 0.00064x).
(B) Regression model for plasma-to-whole-
blood lead concentration ratio to patella bone
lead concentration (y = 0.31 + 0.0033x). (C)
Regression model for plasma-to-whole-blood
lead concentraton ratio totibia bone lead con-
centration (y=0.32+0.0058x).
plasma-blood lead ratio correlated signifi-
cantly and positively with blood lead but
notfingerbone lead, whereas Cake et al. (8)
found that among active workers in a lead
recycling facility the serum-blood lead ratio
correlated significantly and positively with
calcaneal lead, but not with blood lead (8).
In our study of environmentally exposed
adults, we found that the plasma-blood
lead ratio had a range (0.27-0.70%) that
was similar to that reported by Bergdahl
and Skerfving (24) (0.25-0.95%), but our
plasma-blood lead ratio correlated signifi-
candy and positively with patella lead, tibia
lead, and blood lead. Moreover, in a multi-
variate model that included both patella
lead and blood lead, the plasma-blood lead
ratio correlated most strongly with patella
lead. One explanation for the differences
seen in these investigations is that trabecular
bone lead (patella and calcaneus) does, in
fact, exert a predominant influence on
serum (plasma) lead and that this effect
cannot be ascertained by measuring lead in
finger bone (which is mixed trabecular and
cortical bone and, byvirtue ofrelatively low
bone mass, gives rise to less precise bone
lead measurements).
The evidence that the skeleton may be
an endogenous source of lead exposure is
rapidly growing. It is now generally recog-
nized that bone, rather than acting as aper-
manent site of lead deposition, is a meta-
bolically active site which uptakes and
releases lead at a rate determined by lead
exchange at bone surfaces and factors
affecting bone remodeling (5,25). Results
from previous studies of occupationally
exposed subjects have suggested that
whole-blood lead was an important deter-
minant ofplasma lead and that bone lead
might be an important endogenous source
Table3. Multivariate regression models ofplasma
lead levels
Independent
variables Coefficient SE p-Value
Model 1 (R2=0.96)
Blood lead(pg/I) 1.02 0.056 <0.001
Patella lead(pg/g) 0.007 0.002 0.005
Constant -5.79 0.22 <0.001
Model 2(R2=0.97)
Blood lead(pg/I) 1.10 0.004 <0.001
Tibia lead (pg/g) 0.0089 0.056 0.051
Constant -6.15 0.23 <0.001
SE,standard error.
ofplasma lead. For example, Cake et al. (8)
hypothesized that endogenous lead (i.e.,
from bone) partitioned differendy between
serum and red cells than did lead from
exogenous exposures. Although insufficient
data exist to accurately evaluate this
hypothesis, it is supported by our observa-
tion that the plasma-to-blood lead concen-
tration ratio varied more significantly with
bone lead levels than with whole-blood
lead levels. Our study sample was not as
large as that ofCake et al. (n = 49), and the
median blood lead levels measured in our
study were not as high as those measured
in their study (362 pg/I). Nonetheless, our
data are consistent with the hypothesis pro-
posed by Cake et al. Other studies have
yielded indirect evidence of the contribu-
tion ofbone lead stores to plasmalegd.
Ourstudywas limitedbythe fact thatwe
measured bone lead 1-3 months before we
measured plasma and blood lead. This
approach was used because of the need to
obtain information on patella lead levels to
stratify the study population. However,
because lead in the skeleton has a half-life of
years to decades (3), we believe that the
change in bone lead levels over the elapsed
interval was negligible. Therefore, our bone
lead measurements probably adequately
reflect levels at the time ofblood and plasma
sampling. Another limitation ofour study
was the small sample size. However, given
that we selected individuals on the basis of
their bone lead levels, we obtained an ade-
quate level ofvariation in bone lead levels.
Thus we maximized statistical power. The
interrelationships of plasma, patella, and
bloodleadconcentrationswerestrongenough
to be detected and were not confounded or
modified by gender or age. Moreover, the
exclusion ofsubjects older than 50 did not
modifytheobservedrelations.
In this study, the potential for contami-
nation ofplasma by lead from extemal and
internal (hemolysis) sources was evaluated
by means oflead concentration and stable
isotopic composition analyses ofprocedural
collection and processing blanks and total
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iron levels in plasma and whole blood. On
the basis of these analyses, only one subject
was excluded. In previous studies that evalu-
ated the importance ofsample collection and
processing methods for accurate and precise
determination of plasma lead levels (14,1),
lead contamination from external sources
was shown to be an important potential con-
tributor to plasma lead. However, lead cont-
amination due to a non-normal redistribu-
tion of lead from erythrocytes into plasma
during routine handling or due to inadver-
tent hemolysis was also found to be a poten-
tially significant modifier ofplasma lead lev-
els, even when hemolysis was not readily
apparent (15). Analyses ofplasma iron levels
proved to be a reliable indicator ofthe latter
source ofcontamination (15). In our study,
we found no evidence suggesting plasma
contamination due to hemolysis, nor was
there any indication that plasma iron levels
confounded or modified the observed associ-
ation between plasma lead and other bio-
markers. Therefore, we believe that the
observed associations between plasma, whole
blood, and bone lead levels cannot be
explained byinternal lead contamination.
The degree to which the whole-blood
lead level reflects the labile, toxic fraction of
lead in the circulation is not well known,
though it has been suggested that plasma
lead provides a more kinetically responsive
and toxicologically relevant marker of lead
than does whole-blood lead (8,25). The
limitations ofwhole-blood lead measure-
ments as a marker of lead exposure-and,
more importantly, as a biomarker ofreadily
labile and toxic lead-have been considered
for several years (26). Although the skeleton
can certainly contribute lead to the circula-
tion, the impact of various exposure regi-
mens and bone metabolic states on the
nature ofthis relationship is not known.
Until recently, arguments supporting the
evaluation ofplasma lead as an essential step
in the investigation ofbone lead release were
based in part on reports showing little or no
correlation between whole-blood and plasma
lead levels in individuals with low to moder-
ate blood lead levels (e.g., 5-25 pg/dl)
(26-30). Anumber ofthose reports described
an apparent severalfold variation in the rela-
tive partitioning oflead between whole blood
andplasma for agivenwhole-bloodleadlevel.
Our results, however, reflect a fairly well-
defined and precise log-linear relationship
between whole-blood and plasma lead levels,
indicating that individual variation in the rel-
ative distribution of lead between whole
blood and plasma may not be as wide as was
previously believed, particularly among indi-
viduals with low to moderate lead levels in
steady-state exposure with their environment.
Our results strongly support the hypoth-
esis that mobilization oflead from bone may
be a significant determinant ofexposure to
lead and are in agreementwith recent reports
that show an increased bone lead mobiliza-
tion during pregnancy (31). It is possible
that during this period the plasma lead level
increases significandy, posing a potential risk
to the developing fetus, the nursing infant,
the lactating woman, or the pregnant
woman. Further information on these points
is needed. Because bone lead has ahalf-life of
years to decades, our results suggest that
whole-blood lead levels may not accurately
predict the riskofassociated lead toxicityand
that lead can remain a significant threat to
women who are pregnant, who are going to
become pregnant, orwho are menopausal or
postmenopausal, even long after the reduc-
tion orcessation ofexogenous leadexposure.
Finally, the findings of this study may
have great importance in terms of public
health. Given the lack of an agreed-upon
threshold for lead's neurotoxic effect, a
fetotoxic effect may in fact be operative
even among women with relatively low
blood lead levels but a high bone lead bur-
den. Thus, current regulations governing
occupational exposure to lead (in Mexico
and the United States) may not adequately
protect women who may become pregnant.
Additional research is clearly needed to
address this important issue.
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